The acquisition also sparked a rally in other gene therapy biotechnology stocks as investors were hopeful of further M&A prospects down the road. For instance, UniQure (QURE) jumped 31.3% following the news.

Chardan analyst Gbola Amusa highlighted UniQure’s similarities to Spark. The company shows proof-of-concept data for its gene therapies and certain designations from regulators in the U.S. or Europe. UniQure could also be a market leader in hemophilia B.

“We believe the Roche-Spark news supports out (a merger) thesis on UniQure,” Amusa said in a report, adding that “hemophilia gene therapy is seemingly of high interest to big biopharma.”

For more information on the healthcare industry, visit our healthcare category.